Get Started in Minutes
How Krystexxa Copay Assistance Works
1 – Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
2 – Transfer Prescription to AmeriPharma
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
3 – Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
4 – Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.
5 – Nursing Care Coordination
AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
6 – Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
What Is Krystexxa?
Krystexxa is a medication that is used to treat gout. It is a recombinant form of the enzyme uricase, which converts uric acid in our body to other water-soluble metabolites and helps excrete it in urine, thus lowering the serum uric acid in our system. “Recombinant” means that it has been made by combining genetic material from two different sources. In the case of Krystexxa, the mammalian uricase enzyme is produced by a genetically modified strain of bacteria called E. coli.
The generic name of Krystexxa is pegloticase. It is manufactured by Horizon Pharma and was first approved by the FDA in 2010.
Krystexxa is currently only available as a brand name medication, and it comes in 8 mg/ml single-use 2 ml solution vials.
What Is Krystexxa Used For?
Gout is a common form of arthritis. It can affect anyone and is characterized by sudden, severe attacks of pain, redness, and swelling in one or more joints (often the big toe joint). At times symptoms can get worse (called flares), and at other times there might be no symptoms (known as remission). Repeated flares of gout can lead to gouty arthritis, which is a worsening form of arthritis. There is currently no cure for gout, but there are medications that can treat the condition by managing symptoms and preventing flares.
Krystexxa is indicated for the treatment of gout in patients who have tried other conventional medications in their maximum recommended dosages (xanthine oxidase inhibitors such as febuxostat and allopurinol) and failed to have their serum uric acid levels controlled, or in patients for whom these medications are contraindicated.
Krystexxa is NOT indicated for patients who have excessive uric acid levels in their body but who are not showing symptoms of gout (asymptomatic hyperuricemia).
Copay and Financial Assistance
AmeriPharma Specialty Care alleviates financial burdens for patients and their families
Advanced software locates funding sources to match you with top-dollar foundation programs
One of our copay assistance specialists will assist with the application process
Automatic updates will be sent to you and your physician on the status of the funding
Krystexxa Side Effects
- Skin bruising (which can lead to skin discoloration)
- Acute gout attack
- Infusion-related reaction
- Antibody development
- Chest pain
- Worsening of congestive heart failure
- Common cold
- Swelling to the legs, ankles, feet, arms, or hands
- Allergic reactions
- General discomfort
These are not all of the possible side effects that may occur. If you have questions about side effects, call your doctor.
Dosing and Administration
The recommended dose of Krystexxa is 8 mg given once every 2 weeks.
Krystexxa is administered as an intravenous (IV) infusion given over at least 120 minutes after dilution in 250 ml of normal saline. The infusion is repeated once every 2 weeks. Prior to the administration of Krystexxa, patients should be premedicated with antihistamines and corticosteroids (unless directed otherwise by the physician).
Krystexxa should only be administered in a healthcare setting by a healthcare provider prepared to manage potential anaphylaxis.
Patients should be monitored closely for infusion reactions during infusion and for an appropriate period of time after the infusion (1 hour).
What Else Do You Need To Know Before Starting?
Do not receive Krystexxa if you:
- Have a rare blood problem called glucose-6-phosphate dehydrogenase deficiency (G6PD).
- Have had a serious allergic reaction to Krystexxa or any of its ingredients.
Tell your doctor about all your medications and medical conditions before starting treatment.